Comprehensive Bladder Cancer Care in Melbourne

Expert urological diagnosis, treatment, and surveillance from board-certified urologists with over 60 years of combined experience.

Schedule Appointment

Prevalence:6th most common cancer in the U.S.

Key Warning Sign:Blood in urine (hematuria)

Diagnosis Tool:Cystoscopy

Recurrence Rate:Up to 70% for non-muscle-invasive

Understanding Bladder Cancer

What You Need to Know About Bladder Cancer

Early Detection Saves Lives

Bladder cancer is one of the most common cancers affecting the urinary system, with approximately 83,000 new cases diagnosed in the United States each year. It occurs when abnormal cells in the lining of the bladder grow uncontrollably, forming tumors that can range from superficial and highly treatable to invasive and life-threatening.

At Zabinski Urology in Melbourne, FL, our urologists bring decades of combined urological expertise to the diagnosis, treatment, and ongoing surveillance of bladder cancer. The single most important factor in successful bladder cancer outcomes is early detection, and our practice is equipped with advanced cystoscopy capabilities to identify bladder tumors at their earliest and most treatable stages.

If you are experiencing blood in your urine, changes in urination patterns, or have risk factors for bladder cancer, prompt evaluation by an experienced urologist can make a significant difference in your prognosis and quality of life.

Risk Factors

What Increases Your Risk of Bladder Cancer

Understanding the Factors That Contribute to Bladder Cancer Development

Bladder cancer develops when DNA mutations cause cells in the bladder lining (urothelium) to grow abnormally. While the exact trigger varies from person to person, several well-established risk factors significantly increase the likelihood of developing this disease.

Tobacco smoking is the single greatest modifiable risk factor, responsible for roughly half of all bladder cancer cases. Carcinogens absorbed from cigarette smoke are filtered by the kidneys and concentrated in the urine, where they come into direct contact with the bladder lining over time. Occupational exposure to aromatic amines and other industrial chemicals used in dye, rubber, leather, textile, and paint manufacturing also elevates risk considerably.

Other contributing factors include chronic bladder infections or irritation, previous radiation therapy to the pelvic area, certain chemotherapy drugs such as cyclophosphamide, and a family history of bladder cancer. Age is another important factor, with most cases diagnosed in individuals over 55. Men are approximately three to four times more likely than women to develop bladder cancer, though women often present at a more advanced stage due to delayed diagnosis.

Types & Staging

Understanding Bladder Cancer Types and Stages

Why Classification Matters for Your Treatment Plan

Bladder cancer is classified by the type of cell where it originates and how deeply it has invaded the bladder wall. The most common type is urothelial carcinoma (transitional cell carcinoma), which accounts for approximately 90% of all bladder cancers in the United States. Less common types include squamous cell carcinoma and adenocarcinoma.

Staging is critical for determining the appropriate treatment approach. Non-muscle-invasive bladder cancer (stages Ta, Tis, and T1) is confined to the inner lining and has not grown into the muscular wall of the bladder. These cases represent roughly 75% of new diagnoses and are typically managed with transurethral resection and intravesical therapy, with ongoing cystoscopic surveillance.

Muscle-invasive bladder cancer (stage T2 and beyond) has penetrated into the deeper muscle layers of the bladder wall and may spread to nearby lymph nodes or distant organs. This stage requires more aggressive treatment, which may include radical cystectomy, chemotherapy, immunotherapy, or radiation therapy. Our urologists work closely with oncology specialists to coordinate comprehensive care for patients with advanced disease.

Tobacco Use

Smoking is the leading cause of bladder cancer. Carcinogens from tobacco are excreted through the kidneys and accumulate in the urine, directly damaging bladder cells over years of exposure.

Chemical Exposure

Occupational contact with aromatic amines, polycyclic aromatic hydrocarbons, and chemicals used in dye, rubber, and textile industries significantly increases bladder cancer risk.

Chronic Inflammation

Recurrent urinary tract infections, long-term catheter use, and bladder stones cause chronic irritation of the bladder lining, which can promote abnormal cell growth over time.

Genetic Mutations

Inherited mutations in genes such as FGFR3, TP53, and RB1 can increase susceptibility. A family history of bladder cancer raises your risk, particularly if a first-degree relative was affected.

Prior Radiation or Chemotherapy

Pelvic radiation therapy for other cancers and certain chemotherapy agents like cyclophosphamide are known to increase the risk of secondary bladder cancer.

Arsenic in Drinking Water

Prolonged exposure to elevated arsenic levels in drinking water has been linked to higher rates of bladder cancer in certain geographic regions.

Our Expertise

Why Choose Zabinski Urology for Bladder Cancer Care

Trusted Urological Care on the Space Coast

Decades of Experience
In-Office Cystoscopy
Comprehensive Cancer Coordination
Patient-Centered Approach

Application	Purpose	Session Time	Frequency	Setting
Diagnostic Cystoscopy	Initial detection and visualization of bladder tumors	10-20 minutes	As needed for symptom evaluation	In-office
Surveillance Cystoscopy	Monitoring for recurrence after treatment	10-20 minutes	Every 3-12 months based on risk	In-office
Cystoscopy with Biopsy	Tissue sampling for pathological staging and grading	15-30 minutes	When abnormalities are identified	In-office or outpatient

Warning Signs

Signs You Should Be Evaluated for Bladder Cancer

Recognizing Symptoms Early Can Save Your Life

Blood in Urine (Hematuria)
Frequent Urination
Painful Urination
Urgency Without Infection
Pelvic or Flank Pain
Recurrent UTI Symptoms

01 What is the most common early sign of bladder cancer?

Blood in the urine (hematuria) is the most common and often the first symptom of bladder cancer. It may appear as visibly pink, red, or cola-colored urine, or it may only be detected through a microscopic urinalysis. Even a single episode of blood in the urine should be evaluated by a urologist with a cystoscopy to rule out bladder cancer.

02 How is bladder cancer diagnosed?

Bladder cancer is primarily diagnosed through cystoscopy, a procedure in which a thin, flexible camera is inserted through the urethra into the bladder to visually inspect the bladder lining. If abnormal tissue is found, a biopsy is taken and sent to pathology for analysis. Additional imaging such as CT urography may be used to evaluate the upper urinary tract.

03 Is bladder cancer curable if caught early?

Yes. When bladder cancer is detected at an early, non-muscle-invasive stage, the five-year survival rate exceeds 95%. This is why prompt evaluation of symptoms like hematuria is critical. Early-stage tumors can often be removed through minimally invasive transurethral resection, followed by surveillance cystoscopy to monitor for recurrence.

04 How often will I need follow-up cystoscopies after bladder cancer treatment?

Bladder cancer has one of the highest recurrence rates of any cancer, so regular surveillance is essential. Typically, cystoscopy is performed every three months for the first two years, then every six months for the next two years, and annually thereafter. Our urologists will tailor your surveillance schedule based on your specific tumor grade and stage.

05 Does smoking really increase my risk of bladder cancer?

Absolutely. Smoking is the single largest risk factor for bladder cancer, responsible for approximately 50% of all cases. The carcinogens in tobacco smoke are filtered by the kidneys and concentrated in the urine, where they directly damage the cells lining the bladder. Quitting smoking significantly reduces your risk and improves outcomes for those already diagnosed.

06 What is the difference between non-muscle-invasive and muscle-invasive bladder cancer?

Non-muscle-invasive bladder cancer is confined to the inner lining of the bladder and has not grown into the deeper muscle layers. It accounts for about 75% of diagnoses and is generally managed with transurethral resection and intravesical therapy. Muscle-invasive bladder cancer has penetrated into the bladder wall muscle and may require more aggressive treatment such as radical cystectomy, chemotherapy, or immunotherapy.

07 Should I see a urologist if I have blood in my urine but no pain?

Yes, and this is critically important. Painless hematuria is actually the hallmark presentation of bladder cancer. Many patients delay evaluation because the bleeding is intermittent and painless, which can allow a tumor to progress. Any blood in the urine, whether visible or microscopic, warrants a thorough urological evaluation including cystoscopy.

Location129 W Hibiscus Blvd, Suite D
Melbourne , FL, 32901

Emailinfo@zabinskiurology.com

Phone(321) 372-1372

Ready to Start?

Schedule Your Consultation

Scientific References

PubMed (PMID: 33516281) - Lenis AT, et al. Bladder Cancer: A Review. JAMA. 2020;324(19):1980-1991. Comprehensive review of bladder cancer epidemiology, diagnosis, and management.
PubMed (PMID: 29753650) - Babjuk M, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer. Eur Urol. 2017;71(3):447-461. Evidence-based guidelines for diagnosis and treatment of non-muscle-invasive bladder cancer.
PubMed (PMID: 27060645) - Burger M, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-241. Analysis of bladder cancer risk factors including smoking and occupational exposures.
PubMed (PMID: 31557868) - Sylvester RJ, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer. Eur Urol. 2021;80(4):373-388. Recurrence and progression risk stratification for surveillance planning.
PubMed (PMID: 32709135) - Kamat AM, et al. Bladder cancer. Lancet. 2016;388(10061):2796-2810. Overview of bladder cancer pathophysiology, staging, and therapeutic advances.

Comprehensive Bladder Cancer Care in Melbourne

What You Need to Know About Bladder Cancer

What Increases Your Risk of Bladder Cancer

Understanding Bladder Cancer Types and Stages